Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02408549 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT02408549 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 239 participants.
The verdict
NCT02408549, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects \>= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 \[NCT02408523\] study.
Interventions
- DRUG Lacosamide Tablet
- DRUG Lacosamide Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2015-08-03 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02408549
The ClinicalTrials.gov registry entry for NCT02408549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lacosamide Tablet is the first listed.
NCT02408549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02408549 about?
NCT02408549 is a clinical study titled "Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures". Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects \>= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 \[NCT0240852...
What is the current status of trial NCT02408549?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2015-08-03. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT02408549?
The interventions under investigation include: Lacosamide Tablet (DRUG), Lacosamide Oral Solution (DRUG).
Who is sponsoring clinical trial NCT02408549?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.